ECSP11011307A - Comprimidos para terapia de combinacion - Google Patents
Comprimidos para terapia de combinacionInfo
- Publication number
- ECSP11011307A ECSP11011307A EC2011011307A ECSP11011307A ECSP11011307A EC SP11011307 A ECSP11011307 A EC SP11011307A EC 2011011307 A EC2011011307 A EC 2011011307A EC SP11011307 A ECSP11011307 A EC SP11011307A EC SP11011307 A ECSP11011307 A EC SP11011307A
- Authority
- EC
- Ecuador
- Prior art keywords
- tablets
- combination therapy
- formula
- compound
- salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
La invención proporciona formas farmaceuticas sólidas (por ejemplo comprimidos) que comprende un compuesto de Formula I, un compuesto de Formula II, un compuesto de Formula III y una sal de Formula IV.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15065509P | 2009-02-06 | 2009-02-06 | |
US15065209P | 2009-02-06 | 2009-02-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP11011307A true ECSP11011307A (es) | 2011-10-31 |
Family
ID=41722740
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2011011307A ECSP11011307A (es) | 2009-02-06 | 2011-09-06 | Comprimidos para terapia de combinacion |
Country Status (31)
Country | Link |
---|---|
US (2) | US20100285122A1 (es) |
EP (1) | EP2393485B1 (es) |
JP (2) | JP5611242B2 (es) |
KR (2) | KR101738325B1 (es) |
CN (1) | CN102307573B (es) |
AP (1) | AP3250A (es) |
AR (1) | AR075369A1 (es) |
AU (1) | AU2010210598B2 (es) |
BR (1) | BRPI1008664A2 (es) |
CA (1) | CA2750521A1 (es) |
CL (1) | CL2011001885A1 (es) |
CY (1) | CY1116852T1 (es) |
DK (1) | DK2393485T3 (es) |
EA (2) | EA021313B1 (es) |
EC (1) | ECSP11011307A (es) |
ES (1) | ES2548886T3 (es) |
HK (1) | HK1164737A1 (es) |
HR (1) | HRP20151009T1 (es) |
HU (1) | HUE025822T2 (es) |
IL (1) | IL214227A (es) |
MX (1) | MX2011008289A (es) |
NZ (1) | NZ594214A (es) |
PE (1) | PE20110994A1 (es) |
PL (1) | PL2393485T3 (es) |
PT (1) | PT2393485E (es) |
SG (3) | SG10201706215UA (es) |
SI (1) | SI2393485T1 (es) |
SM (1) | SMT201500266B (es) |
TW (1) | TWI444367B (es) |
UY (1) | UY32424A (es) |
WO (1) | WO2010091197A2 (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS54237B9 (sr) | 2006-07-07 | 2019-07-31 | Gilead Sciences Inc | Modulatori farmakokinetičkih svojstava terapeutika |
PL3150586T3 (pl) * | 2007-02-23 | 2020-06-01 | Gilead Sciences, Inc. | Modulatory farmakokinetycznych właściwości środków terapeutycznych |
EA201591353A1 (ru) * | 2008-05-02 | 2016-01-29 | Джилид Сайэнс, Инк. | Применение частиц твердого носителя для улучшения технологических характеристик фармацевтического агента |
EP2826466A1 (en) | 2010-11-19 | 2015-01-21 | Gilead Sciences, Inc. | Therapeutic compositions comprising rilpivirin hcl and tenofovir disoproxil fumarate |
PL2646005T3 (pl) * | 2010-11-29 | 2019-12-31 | Formac Pharmaceuticals N.V. | Sprasowane formulacje uporządkowanych, mezoporowatych krzemionek |
JP6122427B2 (ja) * | 2011-07-07 | 2017-04-26 | ヤンセン・サイエンシズ・アイルランド・ユーシー | ダルナビル複合製剤 |
HRP20161696T4 (hr) | 2011-08-16 | 2023-10-13 | Gilead Sciences, Inc. | Tenofovir alafenamid hemifumarat |
AU2012327170A1 (en) * | 2012-02-03 | 2013-08-22 | Gilead Sciences, Inc. | Therapeutic compounds |
CA2863662A1 (en) * | 2012-02-03 | 2013-08-08 | Gilead Sciences, Inc. | Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections |
EP2819644A1 (en) * | 2012-03-01 | 2015-01-07 | Gilead Sciences, Inc. | Spray dried formulations |
CN103830192A (zh) * | 2012-11-27 | 2014-06-04 | 安徽贝克生物制药有限公司 | 一种可粉末直接压片的富马酸替诺福韦二吡呋酯片剂及制备方法 |
SI3608325T1 (sl) | 2012-12-21 | 2022-09-30 | Gilead Sciences, Inc. | Policiklične-karbamoilpiridonske spojine in njihova farmacevtska uporaba |
JP6667556B2 (ja) | 2015-06-30 | 2020-03-18 | ギリアード サイエンシーズ, インコーポレイテッド | テノホビルおよびエムトリシタビンを含む薬学的製剤 |
JP6621933B2 (ja) | 2015-11-09 | 2019-12-18 | ギリアード サイエンシス インコーポレーテッド | ヒト免疫不全ウイルスを処置するための治療組成物 |
ES2806604T3 (es) | 2016-02-02 | 2021-02-18 | Sandoz Ag | Formas cristalinas de monofumarato de tenofovir alafenamida |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA923641B (en) | 1991-05-21 | 1993-02-24 | Iaf Biochem Int | Processes for the diastereoselective synthesis of nucleosides |
US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
DE10153078A1 (de) * | 2001-10-30 | 2003-05-22 | Degussa | Verwendung von Granulaten auf Basis von pyrogen hergestelltem Siliciumdioxid in pharmazeutischen Zusammensetzungen |
PE20040840A1 (es) * | 2002-11-20 | 2004-12-30 | Japan Tobacco Inc | Derivados de 4-oxoquinolina como inhibidores de la integrasa del vih |
CN100375742C (zh) * | 2002-11-20 | 2008-03-19 | 日本烟草产业株式会社 | 4-氧代喹啉化合物及其用途 |
JP3567162B1 (ja) * | 2002-11-20 | 2004-09-22 | 日本たばこ産業株式会社 | 4−オキソキノリン化合物及びそのhivインテグラーゼ阻害剤としての利用 |
CA2512319A1 (en) | 2003-01-14 | 2004-08-05 | Gilead Sciences, Inc. | Compositions and methods for combination antiviral therapy |
MY134672A (en) | 2004-05-20 | 2007-12-31 | Japan Tobacco Inc | Stable crystal of 4-oxoquinoline compound |
TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
TWI471145B (zh) * | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
RU2008128424A (ru) * | 2005-12-14 | 2010-01-20 | Сипла Лимитед (In) | Фармацевтическая комбинация, включающая нуклеотидный и нуклеозидный ингибиторы обратной транскриптазы (такие как тенофовир и ламивудин) в различных частях дозы |
RS54237B9 (sr) * | 2006-07-07 | 2019-07-31 | Gilead Sciences Inc | Modulatori farmakokinetičkih svojstava terapeutika |
PL3150586T3 (pl) * | 2007-02-23 | 2020-06-01 | Gilead Sciences, Inc. | Modulatory farmakokinetycznych właściwości środków terapeutycznych |
-
2010
- 2010-02-04 BR BRPI1008664A patent/BRPI1008664A2/pt not_active Application Discontinuation
- 2010-02-04 AU AU2010210598A patent/AU2010210598B2/en not_active Ceased
- 2010-02-04 US US12/700,608 patent/US20100285122A1/en not_active Abandoned
- 2010-02-04 CN CN2010800066460A patent/CN102307573B/zh not_active Expired - Fee Related
- 2010-02-04 EA EA201190125A patent/EA021313B1/ru not_active IP Right Cessation
- 2010-02-04 KR KR1020167020504A patent/KR101738325B1/ko not_active Application Discontinuation
- 2010-02-04 PL PL10703766T patent/PL2393485T3/pl unknown
- 2010-02-04 EP EP10703766.5A patent/EP2393485B1/en not_active Revoked
- 2010-02-04 EA EA201491658A patent/EA030123B1/ru not_active IP Right Cessation
- 2010-02-04 CA CA2750521A patent/CA2750521A1/en not_active Abandoned
- 2010-02-04 SG SG10201706215UA patent/SG10201706215UA/en unknown
- 2010-02-04 AP AP2011005857A patent/AP3250A/xx active
- 2010-02-04 PT PT107037665T patent/PT2393485E/pt unknown
- 2010-02-04 NZ NZ594214A patent/NZ594214A/xx not_active IP Right Cessation
- 2010-02-04 DK DK10703766.5T patent/DK2393485T3/en active
- 2010-02-04 JP JP2011549268A patent/JP5611242B2/ja not_active Expired - Fee Related
- 2010-02-04 KR KR1020117020652A patent/KR101645759B1/ko active Application Filing
- 2010-02-04 ES ES10703766.5T patent/ES2548886T3/es active Active
- 2010-02-04 SI SI201031019T patent/SI2393485T1/sl unknown
- 2010-02-04 SG SG2014007744A patent/SG2014007744A/en unknown
- 2010-02-04 SG SG2011056306A patent/SG173544A1/en unknown
- 2010-02-04 PE PE2011001449A patent/PE20110994A1/es active IP Right Grant
- 2010-02-04 HU HUE10703766A patent/HUE025822T2/en unknown
- 2010-02-04 MX MX2011008289A patent/MX2011008289A/es active IP Right Grant
- 2010-02-04 WO PCT/US2010/023226 patent/WO2010091197A2/en active Application Filing
- 2010-02-05 AR ARP100100328A patent/AR075369A1/es unknown
- 2010-02-06 TW TW099103651A patent/TWI444367B/zh not_active IP Right Cessation
- 2010-02-08 UY UY0001032424A patent/UY32424A/es not_active Application Discontinuation
-
2011
- 2011-07-21 IL IL214227A patent/IL214227A/en not_active IP Right Cessation
- 2011-08-05 CL CL2011001885A patent/CL2011001885A1/es unknown
- 2011-09-06 EC EC2011011307A patent/ECSP11011307A/es unknown
-
2012
- 2012-06-12 HK HK12105696.2A patent/HK1164737A1/xx not_active IP Right Cessation
-
2014
- 2014-09-02 JP JP2014178005A patent/JP5911927B2/ja active Active
-
2015
- 2015-02-06 US US14/616,563 patent/US20150150810A1/en not_active Abandoned
- 2015-09-24 HR HRP20151009TT patent/HRP20151009T1/hr unknown
- 2015-10-26 CY CY20151100953T patent/CY1116852T1/el unknown
- 2015-10-28 SM SM201500266T patent/SMT201500266B/it unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP11011307A (es) | Comprimidos para terapia de combinacion | |
CO6511251A2 (es) | Compuestos quimicos | |
EA201200550A1 (ru) | Фармацевтические композиции, включающие bi-1356 и метформин | |
CL2011001254A1 (es) | Combinacion farmaceutica que comprende un anticuerpo que reconoce especificamente a cd38 y al menos melfalan; y su uso para el tratamiento contra el cancer. | |
SV2011004061A (es) | Aril-piridinas como inhibidores de sintasa de aldosterona | |
CL2008000691A1 (es) | Compuestos derivados de dihidro y tetrahidro oxazolopirimidinonas sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la esquizofrenia, epilepsia, entre otras enfermedades. | |
MY163083A (en) | Solid forms of a pharmaceutically active substance | |
EA201200937A1 (ru) | Твердая лекарственная форма тикагрелора | |
BRPI1008498A2 (pt) | Composto, prodroga do composto, medicamento, e, uso de um composto. | |
ECSP12012318A (es) | Inhibidores de pirazolil quinazolina cinasa | |
CL2007003138A1 (es) | Compuestos derivados de anilinopiperazina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. | |
ECSP12011799A (es) | Compuestos de espiropiperidina y uso farmacéutico de los mismos | |
CL2011002267A1 (es) | Compuesto derivado de pirazolopiridina sustituida, inhibidor de la quinasa lrrk2; procedimiento de preparacion de dicho compuesto; composicion farmaceutica; combinacion farmaceutica; uso del compuesto para prevenir o tratar un trastorno seleccionado de cancer y enfermedades neurodegenerativas. | |
UY32535A (es) | Métodos e intermediarios para la preparación de agentes farmacéuticos | |
CR20120296A (es) | Nuevos compuestos de espiropiperidina | |
CL2008003041A1 (es) | Compuestos derivados de acido boronico, inhibidores de proteasoma; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. | |
HN2008001723A (es) | Nitrilos espirociclicos como inhibidores de proteasa | |
HN2012000023A (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
EA200971068A1 (ru) | Триазолиламинопиримидиновые соединения | |
EA201490761A1 (ru) | R(+)-n-формилпропаргиламиноиндан | |
CR11601A (es) | Pirimidil ciclopentanos hidroxilados en forma de inhibidores de akt proteina quinasa | |
ES2415029R1 (es) | Composición farmacéutica y método para inhibir la producción o amplificar la eliminación de la proteína P24. | |
PE20150167A1 (es) | (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel | |
EA201171414A1 (ru) | Ингибиторы белков семейства iap | |
EA201200485A1 (ru) | Перорально распадающаяся фармацевтическая лекарственная форма, содержащая арипипразол |